[
    [
        {
            "time": "",
            "original_text": "[看好评级]医药行业(CRO 行业)深度报告：东风已至 腾飞在即",
            "features": {
                "keywords": [
                    "医药行业",
                    "CRO",
                    "深度报告",
                    "东风已至",
                    "腾飞在即"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CRO"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "[看好评级]医药行业(CRO 行业)深度报告：东风已至 腾飞在即",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "[买入-A评级]泰格医药(300347)季报点评：Q1收入和净利润延续高增长 投资收益具备可持续性",
            "features": {
                "keywords": [
                    "泰格医药",
                    "季报",
                    "Q1",
                    "收入",
                    "净利润",
                    "高增长",
                    "投资收益",
                    "可持续性"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[买入-A评级]泰格医药(300347)季报点评：Q1收入和净利润延续高增长 投资收益具备可持续性",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "泰格医药:业绩符合预期,未来继续保持高速增长",
            "features": {
                "keywords": [
                    "泰格医药",
                    "业绩",
                    "符合预期",
                    "高速增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药:业绩符合预期,未来继续保持高速增长",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]